Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

采用第二代 DES 的双支架策略在治疗分叉病变时无劣势

Yael L. Maxwell

August 26, 2015

News Daily News

No Disadvantage for 2-Stent Strategy in Bifurcation Lesions With Second-Generation DES

Yael L. Maxwell

August 26, 2015

News Daily News

La Estrategia de Doble Stent en Lesiones en Bifurcación con SLF de 2ª Generación No tiene Ninguna Desventaja

Yael L. Maxwell

August 26, 2015

News Daily News

HOST-ASSURE: Promus Element Noninferior to Resolute in All-Comers Population

July 10, 2014

News Daily News

HOST-ASSURE: Promus Element No es Inferior al Resolute en una Población de Pacientes No Seleccionados

July 10, 2014

News Daily News

HOST-ASSURE：在一般人群中，Promus Element不比Resolute差

July 10, 2014

News Daily News

在使用DES接受PCI治疗的患者中，西洛他唑与双倍剂量氯吡格雷一样安全

Yael L. Maxwell

September 20, 2013

News Daily News

El Cilostazol es Seguro como la Dosis Doble de Clopidogrel en Pacientes sometidos a PCI con un SLF

Yael L. Maxwell

September 20, 2013

News Daily News

Cilostazol as Safe as Double-Dose Clopidogrel in Patients Undergoing PCI with DES

Yael L. Maxwell

September 20, 2013

News Conference News ACC 2013

Pair of Studies Show Positive Stent Results at ACC

Yael L. Maxwell

March 08, 2013

News Daily News

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Caitlin E. Cox

December 26, 2012

News Daily News

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Caitlin E. Cox

December 26, 2012

News Daily News

It’s MAGIC: Cell Therapy Reduces Long-term MACE in MI Patients

Jason Kahn

August 24, 2012

News Daily News

Es MAGIC: La terapia con célula reduce los MACE a largo plazo en los pacientes con IM

Jason Kahn

August 24, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

L.A. McKeown

March 25, 2012

News Daily News

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

March 15, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Conference News

EES Associated with Reduced MACE Compared with SES

November 07, 2011

News Daily News

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

October 17, 2011

News Daily News

CILON-T Published: Cilostazol Reduces Platelet Reactivity, Not Events

January 09, 2011

Advertisement

采用第二代 DES 的双支架策略在治疗分叉病变时无劣势

No Disadvantage for 2-Stent Strategy in Bifurcation Lesions With Second-Generation DES

La Estrategia de Doble Stent en Lesiones en Bifurcación con SLF de 2ª Generación No tiene Ninguna Desventaja

HOST-ASSURE: Promus Element Noninferior to Resolute in All-Comers Population

HOST-ASSURE: Promus Element No es Inferior al Resolute en una Población de Pacientes No Seleccionados

HOST-ASSURE：在一般人群中，Promus Element不比Resolute差

在使用DES接受PCI治疗的患者中，西洛他唑与双倍剂量氯吡格雷一样安全

El Cilostazol es Seguro como la Dosis Doble de Clopidogrel en Pacientes sometidos a PCI con un SLF

Cilostazol as Safe as Double-Dose Clopidogrel in Patients Undergoing PCI with DES

Pair of Studies Show Positive Stent Results at ACC

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

It’s MAGIC: Cell Therapy Reduces Long-term MACE in MI Patients

Es MAGIC: La terapia con célula reduce los MACE a largo plazo en los pacientes con IM

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

Celecoxib Enhances DES Efficacy, But at Clinical Cost

EES Associated with Reduced MACE Compared with SES

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

CILON-T Published: Cilostazol Reduces Platelet Reactivity, Not Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content